凯德诊断
CDNA
64.00
-2.68
-4.01%
凯德诊断
US · CDNA
#2371 按市值排名
上市于 1970
64.00
-2.68
-4.01%
实时 - 追踪5344个代码 - 心跳于224秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了4.8个百分点。
机构持股
- 机构持股比例
- 101.17% -4.80pp
- 机构数量
- 276 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund69.57%
Hedge Fund24.67%
Individual/Insider4.41%
Public Company3.46%
Private Company2.00%
Government Pension Fund0.86%
Family Office/Trust0.39%
Insurance Company0.21%
主要股东 截至 2026-06-30
BlackRock
9.31% · 4.81M 股
Vanguard Capital Management, LLC
4.96% · 2.56M 股
State Street Global Advisors
4.77% · 2.47M 股
Deerfield Management Company, L.P.
3.86% · 2.00M 股
ARK Investment Management LLC
3.78% · 1.95M 股
Boston Partners Global Investors, Inc.
3.75% · 1.94M 股
Baron Capital Group, Inc.
3.74% · 1.94M 股
Gagnon Securities, LLC
3.15% · 1.63M 股
Chevy Chase Trust Company
2.78% · 1.44M 股
Geode Capital Management, LLC
2.57% · 1.33M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 12次买入 · 38次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| John Hanna | Chief Executive Officer | 1.26% |
| Peter Maag | Executive Director | 0.57% |
| Abhishek Jain | Chief Financial Officer | 0.49% |
| Fred Cohen | Independent Director | 0.30% |
| Michael Goldberg | Independent Chairperson | 0.28% |
| George Bickerstaff | Independent Director | 0.24% |
| Jeffrey Novack | General Counsel | 0.21% |
| Keith Kennedy | Chief Operating Officer | 0.09% |
| William Hagstrom | Independent Director | 0.08% |
| Alexander Johnson | President of Patient and Testing Services | 0.08% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | Michael Goldberg | Independent Chairperson | Other Acquisition | +588 | -- |
| 2026-09-30 | Keith Kennedy | Chief Operating Officer | Sale to Issuer | -3,018 | $66.23 |
| 2026-09-30 | John Hanna | Chief Executive Officer | Sale to Issuer | -8,511 | $66.23 |
| 2026-09-30 | Jessica Meng | Chief Commercial Officer | Sale to Issuer | -2,619 | $66.23 |
| 2026-09-30 | Jeffrey Novack | General Counsel | Sale to Issuer | -997 | $66.23 |
| 2026-09-11 | Keith Kennedy | Chief Operating Officer | Sale to Issuer | -8,220 | $52.37 |
| 2026-09-11 | Jessica Meng | Chief Commercial Officer | Sale to Issuer | -6,688 | $52.37 |
| 2026-08-16 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -9,122 | $46.38 |
| 2026-08-13 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -7,000 | $45.30 |
| 2026-08-12 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -7,000 | $47.07 |
| 2026-08-11 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -7,000 | $46.89 |
| 2026-08-10 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -7,000 | $47.69 |
| 2026-08-09 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -6,902 | $47.66 |
| 2026-08-04 | George Bickerstaff | Independent Director | Open Market Disposition | -20,000 | $46.29 |
| 2026-08-04 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -46,963 | $46.40 |
| 2026-08-04 | Jeffrey Novack | General Counsel | Automatic Disposition | -2,688 | $46.15–46.75 |
| 2026-08-03 | Michael Goldberg | Independent Chairperson | Open Market Disposition | -44,700 | $47.06 |
| 2026-08-03 | Christine Cournoyer | Independent Director | Open Market Disposition | -16,000 | $46.94 |
| 2026-08-03 | Peter Maag | Executive Director | Intent to Sell (Form 144) | -75,653 | $47.28 |
| 2026-07-31 | Jeffrey Novack | General Counsel | Sale to Issuer | -2,872 | $47.85 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:25 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
凯德诊断 讨论区 0 条评论